Welcome to Multibagg AI
Log in to access personalized features
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2191.90 | 3,639 Cr | 31.60 | 6.01 | 1.09 | 19.03 | 24.66 | 14.52 | ||
380.85 | 3,557 Cr | 34.88 | 4.53 | 0.11 | 12.98 | 12.14 | 6.46 | ||
350.00 | 3,550 Cr | 55.29 | 5.34 | 0.03 | 9.66 | 11.45 | 4.78 | ||
367.10 | 3,359 Cr | 17.23 | 2.17 | 0.54 | 12.58 | 11.51 | 6.92 | ||
1329.30 | 3,282 Cr | 35.22 | 4.01 | 0.00 | 11.39 | 15.94 | 9.52 | ||
461.70 | 3,251 Cr | 12.86 | 1.20 | 0.00 | 2.88 | 3.79 | 6.77 | ||
527.00 | 3,219 Cr | -599.50 | 3.86 | 0.00 | -2.93 | -2.42 | -0.57 | ||
| Median: 7 Co. | — | 461.70 | 3,359 Cr | 31.60 | 4.01 | 0.03 | 11.39 | 11.51 | 6.77 |
Investor Presentation
Q4 FY17
Investor Presentation
Q3 FY17
Investor Presentation
Q2 FY17
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY17
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY16
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY16
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Unichem Laboratories Limited is a pharmaceutical company that manufactures active pharmaceutical ingredients and operates through four divisions. It has five manufacturing facilities across India, enjoying numerous global certifications.
The company has a rich history of collaborations and initiatives, having set up various R&D centers and strategic plants since its inception in 1962, illustrating its commitment to growth and innovation.
Recent strategic moves include a significant acquisition by Ipca Laboratories Limited, which now holds majority control over Unichem, influencing its future trajectory and operational strategies.
Despite divesting some business components in the past, Unichem continues to expand its international presence, notably with a wholly owned subsidiary in China, reflecting its global ambitions.
Pharmaceuticals & Biotechnology
Pharmaceuticals
3,251 Cr
Moderate Risk
12.9
34.1
0.2
1.2
656.85
280.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Unichem Laboratories Ltd (UNICHEMLAB) is currently trading at 446.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Unichem Laboratories Limited is a pharmaceutical company that manufactures active pharmaceutical ingredients and operates through four divisions. It has five manufacturing facilities across India, enjoying numerous global certifications. The company has a rich history of collaborations and initiatives, having set up various R&D centers and strategic plants since its inception in 1962, illustrating its commitment to growth and innovation. Recent strategic moves include a significant acquisition by Ipca Laboratories Limited, which now holds majority control over Unichem, influencing its future trajectory and operational strategies. Despite divesting some business components in the past, Unichem continues to expand its international presence, notably with a wholly owned subsidiary in China, reflecting its global ambitions.
Over the past 52 weeks, Unichem Laboratories Ltd has traded between a low of ₹280.00 and a high of ₹656.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Unichem Laboratories Ltd has a market capitalization of approximately 3,250.63. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Unichem Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 12.86 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,250.63 Cr, Unichem Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Unichem Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Unichem Laboratories Ltd is 12.86. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Unichem’s consolidated Q4 net profit was ₹11 crore, down from ₹53 crore in the same quarter last year, a 79.2% year-on-year decline.
Bearish
6
Neutral
4
Bullish
4
Bearish
7
Neutral
4
Bullish
35
Bearish
1
Neutral
0
Bullish
31
Share Acquisition
Equity Intelligence India Pvt Ltd (portfolio clients including EQ India Fund) acquired 300,000 equity shares (0.43% of equity; 0.42% diluted) of Unichem Laboratories Ltd via open market on 11‑Jun‑2026, raising its holding to 394,375 (0.56%).
Shareholding disclosure
Portfolio management clients of Equity Intelligence India Pvt Ltd (and EQ India Fund) sold 3,00,000 Unichem Laboratories shares in the open market on 11‑Jun‑2026, reducing holding from 6,94,375 (0.99%) to 3,94,375 (0.56%).
Shareholding disclosure
On 11-Jun-2026 Equity Intelligence India Pvt Ltd (portfolio management clients & EQ India Fund) reported an open-market purchase of 300,000 equity shares of Unichem Laboratories; filing shows pre-hold 6,94,375 (0.99%) and post-hold 3,94,375 (0.56%), an arithmetic inconsistency with the reported acquisition.
